Review of GLP-1 agonist developments for gestational diabetes explores efficacy evidence, safety concerns, and the potential role of these drugs in pregnancy-related metabolic disease.
Key findingReview of GLP-1 agonist developments for gestational diabetes explores efficacy evidence, safety con
What the researchers found
Review of GLP-1 agonist developments for gestational diabetes explores efficacy evidence, safety concerns, and the potential role of these drugs in pregnancy-related metabolic disease.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Review identified trials testing three specific GLP-1 drugs (liraglutide, semaglutide, exenatide) for gestational diabetes from ClinicalTrials.gov.
How the study worked
In publication.
Who was studied
Pregnant women with gestational diabetes across registered clinical trials
What this study cannot tell us
In publication.
How to read the evidence
Based on study design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide therapeutic knowledge.
Questions still open
- Long-term implications?
- Comparison to evidence?
- Next research?
Common questions
What does this mean?
How reliable?
Read the original research
New developments in GLP-1 agonist therapy for gestational diabetes: Systematic review on liraglutide, semaglutide, and exenatide from ClinicalTrials.gov.
Medicine, 104(40), e44917
Citation
Alshehri, Fahad S. (2025). New developments in GLP-1 agonist therapy for gestational diabetes: Systematic review on liraglutide, semaglutide, and exenatide from ClinicalTrials.gov.. Medicine, 104(40), e44917. https://doi.org/10.1097/MD.0000000000044917